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Haloperidol is a classical antipsychotic drug while olanzapine is an atypical antipsychotic drug commonly used for the treatment of schizophrenia and other psychosis. Atypical antipsychotics, such as olanzapine and risperidone, exert less selective activity on various neurotransmitter receptors Sertindole is an antipsychotic drug with a unique pharmacological profile. Clozapine is the reference drug for atypical antipsychotics.
Mice were treated chronically with haloperidol (0.125 and 0.25 mg/kg, n=10), olanzapine (1 and 2 mg/kg, n=9-10), clozapine (1.25 and 2.5 mg/kg, n=8-10), risperidone (0.25 and 0.50 mg/kg, n=9-10), sertindole (1.3 and 2.5 mg/kg, n=8-10) for 15 days. Since the genes involved in neurite remodeling are among the primary targets of regulation, the effects of chronic administration of drugs on FGF2,synapsin and NGF levels in the hippocampus of mice were determined using quantitative real-time polymerase chain reaction (RT-PCR).
Our results suggest that administration of the conventional antipsychotic haloperidol and atypical antipsychotic clozapine, olanzapine, risperidone and sertindole increased the expression of FGF2, synapsin and NGF and in the mice hippocampus. Thus chronic administration of clozapine olanzapine,, risperidone and sertindole may promote neuroplasticity via the up-regulation of neutropic factors.
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A decrease in protein level and a missense polymorphism of KIF17 are associated with schizophrenia Abstract It has been shown that the dysfunction of N-methyl-D-asparate (NMDA) receptors-mediated neurotransmission plays a role in the pathophysiology of schizophrenia. Especially, GluN2B, a subunit of NMDA receptors, associated trafficking complex is altered in the prefrontal cortex of schizophrenia. The kinesin superfamily motor protein 17 (KIF17) is known as a transporter of NR2B.Previous studies showed that a structural variant of KIF17 gene is associated with a schizophrenic phenotype. Therefore, here we investigated KIF17 levels in postmortem prefrontal cortex in schizophrenia and the association of a missense polymorphism (Ile341Val) in KIF17 with schizophrenia. The protein expression of KIF17 in schizophrenic postmortem brains was significantly lower than that in controls. Next, the association of missense polymorphisms (rs631375, rs13375609, rs522496 and rs2296225) of KIF17 gene in 567 schizophrenia and 710 healthy subjects was examined. Both genotypic distribution and allelic frequency of rs2296225 polymorphism were significantly different between the chronic schizophrenia subjects and controls. However, our findings described above were not replicated with the independent subjects (555 schizophrenia and 814 healthy controls). Furthermore, the two alleles of rs2296225 polymorphism did not affect the mRNA expression of KIF17. These results suggest that the dysfunction of KIF17 might be involved in the pathophysiology of schizophrenia.
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Gender-specific associations of the brain-derived neurotrophic factor Val66Met polymorphism with neurocognitive and clinical features in schizophrenia Sung-Wan Kim, Ju-Yeon Lee, Hee-Ju Kang, Seon-Young Kim, KyungYeol Bae, Jae-Min Kim, Il-Seon Shin, Jin-Sang Yoon* Department of Psychiatry, Chonnam National University Medical School, Gwang-ju, Korea Abstract Objective: To explore associations of the brain-derived neurotrophic factor (BDNF) Val66Met polymorphism with cognitive functioning and psychopathology in patients with schizophrenia. Methods: We included 133 subjects [71 females (53.4%) and 62 males (46.6%)] meeting the DSM-IV criteria for schizophrenia who were in the post-acute stage of the disease. BDNF Val66Met genotypes were identified via polymerase chain reaction. The computerized neurocognitive function battery, Positive and Negative Syndrome Scale (PANSS), Calgary Depression Scale for Schizophrenia (CDSS), Social and Occupational Functioning Scale (SOFAS), and the Subjective Well-Being Under Neuroleptic Treatment (SWN-K) were administered. Gender-stratified subanalysis was also conducted to identify gender-specific patterns in the findings. Results: In male patients, no significant difference in any measure by BDNF genotype was evident. In female patients, scores on the CDSS (p-value = 0.045) and total PANSS (p-value < 0.001) and all subscales were significantly higher in valine (Val) carriers. In addition, scores on the SOFAS (p-value = 0.008) and SWN-K (p-value = 0.025) were significantly lower in Val carriers. In terms of neurocognitive measures, female patients with the Val allele had significantly poorer reaction times (p-value = 0.004) and fewer correct responses (p-value = 0.001) on the Continuous Performance Test (CPT) and the Trail Making Test (parts A and B) (p-value = 0.048 and 0.033, respectively). After adjustment of PANSS total scores and log-transformed CDSS scores, CPT outcomes were significantly poorer in female patients with than in those without the Val allele (p-value = 0.015 and 0.018, respectively). Conclusion: Gender-specific associations of the Val allele with poor neurocognitive function and more severe psychopathology were evident. Further studies are required to explore the mechanisms of these differences and the potential utility of the BDNF genotype as a predictor of outcome in patients with schizophrenia.
